GlassScriptPhysician profile
Eva Joseph
NPI 1346614898
$9,718.89
in general payments reported to CMS, 2019-2025
53 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,643 · 2022: $1,559 · 2023: $1,601 · 2024: $2,810 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,321 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,320.92 |
| Education | $195.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $955.51 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $786.26 | 2022-2025 | Keytruda, Lynparza |
| Novartis Pharmaceuticals Corporation | $710.09 | 2022-2025 | |
| Celgene Corporation | $534.21 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| Astellas Pharma US INC | $494.69 | 2023-2025 | Padcev, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $488.05 | 2021-2025 | Reblozyl, Opdualag, Opdivo |
| Pfizer INC. | $423.79 | 2022-2025 | |
| Shield Therapeutics INC | $388.63 | 2024 | |
| Seagen INC. | $321.01 | 2021-2023 | Tukysa, Padcev |
| Daiichi Sankyo INC. | $320.83 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Jazz Pharmaceuticals INC. | $313.05 | 2021-2025 | |
| Amgen INC. | $301.74 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $280.51 | 2021-2025 | Calquence, Lynparza |
| Incyte Corporation | $266.37 | 2021-2025 | Monjuvi, Pemazyre, Jakafi |
| Genentech USA, INC. | $261.43 | 2021-2023 | Tecentriq |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.